Literature DB >> 30684593

Gut microbiome and cancer immunotherapy.

Weina Li1, Yu Deng2, Qian Chu3, Peng Zhang4.   

Abstract

Microbiome is becoming crucial in that the balance between human health and disease can be mediated by the gut microbiome. The gut microbiome can modulate the host immune system both locally and systemically. Cancer immunotherapy has emerged as a promising way in the treatment of patients with cancer. Accumulating evidence supports that microbiome affects the therapeutic efficacy of cancer immunotherapy, particularly immune checkpoint inhibitors. Here, we discuss the mutual relationship among gut microbiome, cancer, immunity, and cancer immunotherapy, with a focus on immunotherapy. Also, we briefly introduce the relevant challenges that affect the therapeutic efficacy and present the possible solutions.
Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cancer immunotherapy; Gut microbiome; Immunity

Mesh:

Year:  2019        PMID: 30684593     DOI: 10.1016/j.canlet.2019.01.015

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  45 in total

Review 1.  Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review.

Authors:  Maleka Najmi; Tiffaney Tran; Russell G Witt; Kelly C Nelson
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-25

Review 2.  Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.

Authors:  Yingying Li; Shiyuan Wang; Mengmeng Lin; Chunying Hou; Chunyu Li; Guohui Li
Journal:  Front Med       Date:  2022-06-01       Impact factor: 9.927

3.  Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not?.

Authors:  Pu Xiaoyu; Ge Chao; Dong Lihua; Chang Pengyu
Journal:  Gut Microbes       Date:  2020-03-27

Review 4.  Immune checkpoint blockade in renal cell carcinoma.

Authors:  Phillip M Rappold; Andrew W Silagy; Ritesh R Kotecha; Ari A Hakimi
Journal:  J Surg Oncol       Date:  2021-03       Impact factor: 3.454

Review 5.  The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients.

Authors:  Alexander R Moschen; Yossi Sammy; Zoe Marjenberg; Amy B Heptinstall; Nick Pooley; Agnieszka M Marczewska
Journal:  Curr Oncol Rep       Date:  2022-03-24       Impact factor: 5.945

Review 6.  The Bacterial Microbiota of Gastrointestinal Cancers: Role in Cancer Pathogenesis and Therapeutic Perspectives.

Authors:  Lina Elsalem; Ahmad A Jum'ah; Mahmoud A Alfaqih; Osama Aloudat
Journal:  Clin Exp Gastroenterol       Date:  2020-05-06

Review 7.  Intestinal microbiota: a new force in cancer immunotherapy.

Authors:  Zhujiang Dai; Jingqiu Zhang; Qi Wu; Huiwen Fang; Chunfeng Shi; Zhen Li; Chaobiao Lin; Dong Tang; Daorong Wang
Journal:  Cell Commun Signal       Date:  2020-06-10       Impact factor: 5.712

8.  Gut Dysbiosis Thwarts the Efficacy of Vaccine Against Mycobacterium tuberculosis.

Authors:  Sajid Nadeem; Sudeep K Maurya; Deepjyoti K Das; Nargis Khan; Javed N Agrewala
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

Review 9.  Factors Affecting Gut Microbiome in Daily Diet.

Authors:  Qi Su; Qin Liu
Journal:  Front Nutr       Date:  2021-05-10

Review 10.  Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?

Authors:  Nuttavut Sumransub; Kornpong Vantanasiri; Ajay Prakash; Emil Lou
Journal:  Mol Ther Oncolytics       Date:  2021-05-14       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.